Literature DB >> 24366497

A review of the clinical diagnosis and therapy of cholangiocarcinoma.

Denghua Yao1, Vamsi Krishna Kunam, Xiao Li.   

Abstract

Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy worldwide. The incidence of intrahepatic CCA is increasing, whereas that of extrahepatic CCA is decreasing. This review looks at the new advances that have been made in the management of CCA, based on a PubMed and Science Citation Index search of results from randomized controlled trials, reviews, and cohort, prospective and retrospective studies. Aggressive interventional approaches and new histopathological techniques have been developed to make a histological diagnosis in patients with high risk factors or suspected CCA. Resectability of the tumour can now be assessed using multiple radiological imaging studies; the main prognostic factor after surgery is a histologically negative resection margin. Biliary drainage and/or portal vein embolization may be performed before extended radical resection, or liver transplantation may be undertaken in combination with neoadjuvant chemotherapy or chemoradiotherapy. Though many advances have been made in the management of CCA, the standard modality of treatment has not yet been established. This review focuses on the clinical options for different stages of CCA.

Entities:  

Keywords:  Cholangiocarcinoma; diagnosis; malignant biliary obstruction; photodynamic therapy; review; therapy

Mesh:

Substances:

Year:  2013        PMID: 24366497     DOI: 10.1177/0300060513505488

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  11 in total

1.  A Serendipitous Find: A Case of Cholangiocarcinoma Identified Incidentally After Acute Liver Injury Due to Cascara sagrada Ingestion.

Authors:  Elizabeth S Nakasone; Jinichi Tokeshi
Journal:  Hawaii J Med Public Health       Date:  2015-06

Review 2.  Locoregional Therapies of Cholangiocarcinoma.

Authors:  Christof M Sommer; Hans U Kauczor; Philippe L Pereira
Journal:  Visc Med       Date:  2016-12-05

Review 3.  Update on the Diagnosis and Treatment of Cholangiocarcinoma.

Authors:  Bryan Doherty; Vinod E Nambudiri; William C Palmer
Journal:  Curr Gastroenterol Rep       Date:  2017-01

4.  External validation study of the 8th edition of the American Joint Committee on Cancer staging system for perihilar cholangiocarcinoma: a single-center experience in China and proposal for simplification.

Authors:  Jian Zhao; Wei Zhang; Jun Zhang; Wen-Jie Ma; Si-Yun Liu; Fu-Yu Li; Bin Song
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Cohort profile: cholangiocarcinoma screening and care program (CASCAP).

Authors:  Narong Khuntikeo; Nittaya Chamadol; Puangrat Yongvanit; Watcharin Loilome; Nisana Namwat; Paiboon Sithithaworn; Ross H Andrews; Trevor N Petney; Supannee Promthet; Kavin Thinkhamrop; Chaiwat Tawarungruang; Bandit Thinkhamrop
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

6.  Prognostic value of inflammation-based markers in patients with recurrent malignant obstructive jaundice treated by reimplantation of biliary metal stents: A retrospective observational study.

Authors:  Hao Jin; Qing Pang; Huichun Liu; Zongkuang Li; Yong Wang; Yimin Lu; Lei Zhou; Hongtao Pan; Wei Huang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma.

Authors:  Zhiqiang Chen; Tong Lin; Xiaozhong Liao; Zeyun Li; Ruiting Lin; Xiangjun Qi; Guoming Chen; Lingling Sun; Lizhu Lin
Journal:  Chin Med       Date:  2021-01-21       Impact factor: 5.455

8.  Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup.

Authors:  Jian Zhao; Wei Zhang; Fu-Yu Li; Bin Song; Jun Zhang; Yun-Tian Chen; Wen-Jie Ma; Si-Yun Liu
Journal:  Cancer Manag Res       Date:  2020-12-22       Impact factor: 3.989

9.  Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.

Authors:  Mingming Zhang; Yuyao Yin; Robert G Dorfman; Tianhui Zou; Yida Pan; Yang Li; Yuming Wang; Qian Zhou; Lixing Zhou; Bo Kong; Helmut Friess; Jun Zhang; Shimin Zhao; Lei Wang; Xiaoping Zou
Journal:  Oncotarget       Date:  2017-07-28

10.  Methylation-Mediated Silencing of GATA5 Gene Suppresses Cholangiocarcinoma Cell Proliferation and Metastasis.

Authors:  Peng Liu; Teng-Fei Zhou; Bao-An Qiu; Ying-Xiang Yang; Yong-Jian Zhu; Yang An; Wen-Chao Zhao; Yin-Tao Wu; Peng-Fei Ma; Jing-Bo Li; Nian-Xin Xia
Journal:  Transl Oncol       Date:  2018-03-13       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.